Alcohol Use DisorderPEERSIADNCT06381609
Peer Support in Alcohol Dependence
A study testing Quality life questionnaire AQoLS, Quality life questionnaire Euroqol EQ-5D-5L and Peer support consultations in people with Alcohol Use Disorder, run by Hospices Civils de Lyon at 5 sites in France.
Trial summary
Alcohol use disorder (AUD) affects between 4% and 6% of French adults, and requires appropriate medical treatment. However, 20-40% of patients with AUD are lost to follow-up at an early stage. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alcohol Use Disorder
- What is being tested?
- Quality life questionnaire AQoLS, Quality life questionnaire Euroqol EQ-5D-5L and Peer support consultations
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 626 participants
- Where
- 5 sitesFrance
- Study dates
- 19 Oct 2026to 19 Apr 2030
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged ≥ 18
- Socially insured
- Meeting DSM-5 criteria for alcohol use disorder (AUD)
- Abstinent from alcohol and involved in supervised alcohol withdrawal for at least 5 days and no more than 21 days (outpatient or inpatient)
- Starting a post-detoxification outpatient program
Who cannot join
- Other severe substance use disorder, i.e. DSM-5 criteria ≥ 6 (excluding tobacco)
- Patient under protective measure (safeguard measure, guardianship) or deprived of liberty or in ordered care and hospitalization measures without consent.
- Inability to communicate and express oneself orally in French, compromising the possibility of exchanges between the Peer support and the patient.
- Psychiatric or cognitive comorbidities making inclusion impossible, at the investigator's discretion.
- Individual accompaniment by a Peer support in the 15 days prior to inclusion.
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
France5 sites, 5 recruiting
- Recruiting
CH Le Vinatier
Bron, 69500
Monique GUENIN, MD-PhD, +33 4 37 91 55 55, monique.guenin@ch-le-vinatier.fr
Monique GUENIN, MD-PhD
- Not yet recruiting
Hôpital Beaujon
Clichy, 92110
Delphine MOISAN, MD-PhD, +33 1 40 87 58 82, delphine.moisan@aphp.fr
Delphine MOISAN, MD-PhD
- Not yet recruiting
GH Nord, Hospices Civils de Lyon
Lyon, 69004
Benjamin ROLLAND, Professor
Benjamin ROLLAND, Professor
- Not yet recruiting
CHS St Anne
Paris, 75014
Clément VANSTEENE, MD-PhD
Clément
- Not yet recruiting
Bichat Hospital
Paris, 75018
Pierre-Alexis GEOFFROY, MD-PhD, +33 1 40 25 82 60, pierrealexis.geoffroy@aphp.fr
Pierre-Alexis GEOFFROY, MD-PhD
About this study
Official title: Contribution of Addiction Peer Support on Adherence to Care and Clinical Outcomes in Alcohol Dependence: a Prospective Controlled Trial With Medico-economic Component
Alcohol use disorder (AUD) affects between 4% and 6% of French adults, and requires appropriate medical treatment.
However, 20-40% of patients with AUD are lost to follow-up at an early stage. Consequently, it is important for addiction departments to implement and evaluate innovative tools and interventions, including the involvement of peer support, to help patients remain in care, and to assess whether peer support has a positive impact on their clinical outcome.
Read more
Addiction peer support specialists (APSSs) are individuals who have personally experienced addiction, and who have decided to use their experience to assist other people going through a similar situation, after completing a specific official graduation.
Compared to other caregivers, APSSs may induce in patients a sense of identification which could improve the patient motivation to engage and remain in care.
This is the main hypothesis and the main scientific objective of the PEERSIAD study, which will aim to confirm that accompanying patients with AUD using APSSs after alcohol detoxification, reduces the rate of lost-to-follow-up and improves the overall clinical outcome.
- Conditions
- Alcohol Use Disorder
- Being tested
- Quality life questionnaire AQoLS, Quality life questionnaire Euroqol EQ-5D-5L, Peer support consultations
- Keywords
- Peer support, Addiction, Alcohol
- Medical subject headings
- Alcoholism, Behavior, Addictive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quality life questionnaire AQoLSBehavioural
Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion
Quality life questionnaire Euroqol EQ-5D-5LBehavioural
Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion
Peer support consultationsOther
For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months.
Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up
| Study group | Role | What they receive |
|---|---|---|
| Peer support Group | Experimental | 313 patients will be recruited over 3 years in the peer support group. Patients will be accompanied by an addiction peer support specialist, as part of an "add-on" follow-up compared with conventional follow-up (same management as in the control group). Receives: Behavioral: Quality life questionnaire AQoLS; Behavioral: Quality life questionnaire Euroqol EQ-5D-5L; Other: Peer support consultations |
| Control Group | Active comparator | 313 patients will be recruited over 3 years in the control group. Patients will receive "as usual" outpatient abstinence-maintenance follow-up, with consultations of all kinds (medical, psychological, nursing, group, etc.) Receives: Behavioral: Quality life questionnaire AQoLS; Behavioral: Quality life questionnaire Euroqol EQ-5D-5L |
What is being measured
The primary outcome is the main question the study is designed to answer.
Unplanned cessation of care at 6 months
The unplanned cessation of care at 6 months, excluding consultations with an APSS, with no further contact in the following month, is defined as having had a last planned consultation that was not fulfilled between M0 and M6
Measured: At 6 months after inclusion
Secondary outcomes (23)
Number of unfulfilled consultations
The number of unfulfilled consultations (scheduled consultations, excluding Peer Support consultations, without patient's visit with or without justification) over the 6-month study follow-up period, collected from the medical records of the addictology department.
Measured: 6 months after inclusion
Euroqol-5D-5L questionnaire score
The differential cost-utility ratio, in relation to the innovative strategy including a Peer Support, will be assessed using the Euroqol-5D-5L questionnaire (EQ-5D-5L).
Measured: At inclusion, 3 and 6 months after inclusion
Difference in costs (in euros)
An additional analysis will be carried out if the cost-utility ratio is positive: Difference in costs (in euros) for the payer (French compulsory health insurance) between a scenario in which the innovative management is implemented and disseminated in practice and on French territory, and a scenario in which usual follow-up is maintained.
Measured: At 1, 2 and 3 years after the beginning of implementation on French territory
Number of AUD criteria according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Measured: At inclusion, 3 and 6 months after inclusion
Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score
Measured: At inclusion, 3 and 6 months after inclusion
average number of standard drinks declared per week
Measured: At inclusion, 3 and 6 months after inclusion
Alcohol Quality of Life Scale (AQoLS) score
Changes in quality of life will be measured using the AQoLS
Measured: At inclusion, 3 and 6 months after inclusion
State-Trait Anxiety Inventory (STAI-Y) score
Changes in levels of anxiety will be measured using STAI-Y
Measured: At inclusion, 3 and 6 months after inclusion
Montgomery-Åsberg Depression Rating Scale (MADRS) score
Changes in levels of depression will be measured using MADRS
Measured: At inclusion, 3 and 6 months after inclusion
Cannabis Use Disorders Identification Test - Revised (CUDIT-R) score
Changes in the severity of cannabis use will be measured by the CUDIT-R score
Measured: At inclusion, 3 and 6 months after inclusion
type of opioid use
Measured: At inclusion, 3 and 6 months after inclusion
frequency of opioid use
Measured: At inclusion, 3 and 6 months after inclusion
type of psychostimulant use
Measured: At inclusion, 3 and 6 months after inclusion
frequency of psychostimulant use
Measured: At inclusion, 3 and 6 months after inclusion
Fagerström test score
Tobacco use will be measured by the Fagerström test
Measured: At inclusion, 3 and 6 months after inclusion
Health Care Satisfaction Questionnaire (HCSQ) score
Patient's satisfaction will be measured by HCSQ questionnaire
Measured: At 6 months after inclusion
Number of hospitalisations
Measurement of the number of hospitalisations related or not to the AUD and the ratio of total hospital days to number of hospital admissions (based on medical records and patient interviews)
Measured: At 6 months after inclusion
Service organization description
Measured: Before setting up of the study
Description of type of support and missions performed by Peer Support
Measured: After last visit of last patient (around 3,5 years after first inclusion)
Acceptability of Intervention Measure (AIM) score
AIM score measured in Peer Support and medical staff
Measured: After last visit of last patient (around 3,5 years after first inclusion)
AIM score
AIM score measured in patients
Measured: At 6 months after inclusion
Adoption of intervention
adoption of intervention will be assessed through semi-structured interviews and measurement of the number of patients followed-up versus the number of eligible patients, refusals to be accompanied by APSS, and premature discontinuation of follow-up
Measured: After last visit of last patient (around 3,5 years after first inclusion)
Intervention fidelity
intervention fidelity will be assessed by monitoring APSS activity indicators, describing deviations from the protocol and semi-structured interviews
Measured: After last visit of last patient (around 3,5 years after first inclusion)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2024
- Study start19 Oct 2026
- Primary completion19 Apr 2030 (estimated)
- Study completion19 Apr 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 626 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Benjamin ROLLAND, Principal investigator, Hopsices Civils de Lyon
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06381609
- Sponsor's protocol ID
- 69HCL22_0901
- Acronym
- PEERSIAD
- Status last verified
- Oct 2026
- First submitted
- 2 Apr 2024
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No